2024
Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers
DiSilvestro J, Haddad J, Robison K, Beffa L, Laprise J, Scalia-Wilbur J, Raker C, Clark M, Lokich E, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers. Journal Of Women's Health 2024, 33: 624-628. PMID: 38488054, DOI: 10.1089/jwh.2023.0621.Peer-Reviewed Original ResearchRisk-reducing surgeryRisk-reducing strategiesMutation carriersGenetic testingIncreased screeningOvarian cancer risk reductionRisk of ovarian cancerRisk-reducing medicationsCancer risk reductionBRCA1/2 mutation carriersCross-sectional surveyOvarian cancerHigh-risk populationScreening utilizationEarly detection of ovarian cancerCombination of transvaginal ultrasoundCombined oral contraceptive pillDetection of ovarian cancerYears of ageSerum CA125 measurementOral contraceptive pillsFisher's exact testScreening protocolFemale participantsRisk reduction
2022
Financial toxicity in patients with advanced solid malignancies participating in early-phase clinical trials.
Blanter J, Werner M, Kier M, Hapanowicz O, Itani M, Ahmad M, DeMerchant M, Eder J, Galsky M, Hammad A, King P, Lachowicz M, Lucas N, Marron T, Shelton G, Wu K, Xu S, LoRusso P, Hofstatter E, Doroshow D. Financial toxicity in patients with advanced solid malignancies participating in early-phase clinical trials. Journal Of Clinical Oncology 2022, 40: 267-267. DOI: 10.1200/jco.2022.40.28_suppl.267.Peer-Reviewed Original ResearchOvarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383)
DiSilvestro J, Dexter J, Haddad J, Beffa L, Raker C, Laprise J, Wilbur J, Clark M, Bradford L, Brown A, Hofstatter E, Dalela D, Toland M, Robison K, Stuckey A. Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383). Gynecologic Oncology 2022, 166: s195-s196. DOI: 10.1016/s0090-8258(22)01605-5.Peer-Reviewed Original ResearchFemale BRCA mutation carriersOral contraceptive pillsOvarian cancer screeningBRCA mutation carriersOvarian cancerMutation carriersGenetic testingGynecologic oncologistsContraceptive pillsCancer screeningExact testBRCA 1/2 mutation carriersCombined oral contraceptive pillBRCA mutation typeRisk-reducing surgeryPrimary care providersHigh-risk populationHalf of womenBRCA1/2 mutation carriersPossible early detectionFisher's exact testCross-sectional surveyGenetic counselorsCA 125Surgical optionsThe Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients
Trant A, Chagpar A, Wei W, Neumeister V, Rimm D, Stavris K, Lurie B, Frederick C, Andrejeva L, Raghu M, Killelea B, Horowitz N, Lannin D, Knill-Selby E, Sturrock T, Hofstatter E. The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients. Integrative Cancer Therapies 2022, 21: 15347354221137290. PMID: 36444764, PMCID: PMC9716631, DOI: 10.1177/15347354221137290.Peer-Reviewed Original ResearchConceptsTumor volumeBlack cohoshSitu patientsDuctal carcinomaAnti-inflammatory effectsTumor cellular proliferationBreast cancer treatmentCellular proliferationWilcoxon signed-rank testDCIS patientsAdverse eventsEligible subjectsWindow trialsCore biopsyInvasive diseaseKi67 expressionSigned-rank testBreast cancerGrade 3Hormone changesPatientsQuantitative immunofluorescenceBC extractSignificant toxicityCancer treatment
2021
Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.
Afghahi A, Marsh S, Winchester A, Gao D, Parris H, Axell L, Ellisen L, Hofstatter E, Kurian A, Wood M, Zakalik D, Mullin C, Caswell-Jin J, Borges V, Tung N. Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study. Journal Of Clinical Oncology 2021, 39: 10531-10531. DOI: 10.1200/jco.2021.39.15_suppl.10531.Peer-Reviewed Original ResearchCHEK2 pathogenic variantsRecurrence scoreCase-control studyMedian RSBreast cancerPathogenic variantsHigh riskRisk groupsMutation statusHER2-negative BC patientsPR-negative breast cancerMulti-site case-control studyPatient-level clinical dataRS risk groupsLymph node statusHigh recurrence scoreLow-risk groupGermline pathogenic variantsSporadic breast cancerGenetic testing resultsElectronic medical recordsAdjuvant therapyChemotherapy benefitNode statusT stage
2020
Reproductive decision making and partnering in BRCA1/2 mutation carriers
DiSilvestro J, Haddad J, Robison K, Beffa L, Laprise J, Wilbur J, Raker C, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. Reproductive decision making and partnering in BRCA1/2 mutation carriers. Gynecologic Oncology 2020, 159: 260-261. DOI: 10.1016/j.ygyno.2020.05.449.Peer-Reviewed Original ResearchBarriers to hormone replacement therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers
DiSilvestro J, Haddad J, Robison K, Beffa L, Laprise J, Wilbur J, Raker C, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. Barriers to hormone replacement therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers. Gynecologic Oncology 2020, 159: 260. DOI: 10.1016/j.ygyno.2020.05.448.Peer-Reviewed Original Research
2019
Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago.
Parkinson G, Chagpar A, Alleyne-Mike K, Nunez-Smith M, Zhou A, Servais L, Hofstatter E. Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Journal Of Clinical Oncology 2019, 37: 6574-6574. DOI: 10.1200/jco.2019.37.15_suppl.6574.Peer-Reviewed Original ResearchFemale breast cancer patientsBreast cancer patientsNCCN criteriaCancer patientsGenetic counselingHigher breast cancer mortality ratesYounger ageHBOC testingBreast cancer mortality ratesOvarian cancer syndromeBreast cancer treatmentBreast cancer casesCancer mortality ratesYears of ageTesting servicesFurther genetic counselingPre-test counselingBreast cancer diagnosisNCCN guidelinesChart reviewFemale patientsOncology unitBreast cancerCancer casesFamily history
2018
Breast cancer risk perception and adherence to u.s. cancer prevention guidelines.
Eckroate J, Chagpar A, Hofstatter E. Breast cancer risk perception and adherence to u.s. cancer prevention guidelines. Journal Of Clinical Oncology 2018, 36: 1554-1554. DOI: 10.1200/jco.2018.36.15_suppl.1554.Peer-Reviewed Original ResearchDurvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original ResearchThe effect of black cohosh on Ki67 levels in DCIS patients.
Hofstatter E, Trant A, Stavris K, Horowitz N, Killelea B, Lannin D, Neumeister V, Rimm D, Chagpar A. The effect of black cohosh on Ki67 levels in DCIS patients. Journal Of Clinical Oncology 2018, 36: e13541-e13541. DOI: 10.1200/jco.2018.36.15_suppl.e13541.Peer-Reviewed Original Research
2017
Genetic Evaluation for Women at Increased Risk
Brierley K, Healy C, Hofstatter E. Genetic Evaluation for Women at Increased Risk. 2017, 15-30. DOI: 10.1007/978-3-319-59198-8_2.Peer-Reviewed Original ResearchOvarian cancerFamily historyHereditary breastUS Preventative Services Task ForceModerate-penetrance genesHereditary cancer predispositionHealth care providersManagement of individualsBRCA mutationsPretest counselingCare providersGenetic testing optionsMultidisciplinary teamRisk assessmentInformed consentPatientsCancerTesting optionsGenetic counseling processFurther risk assessmentCancer predispositionCancer geneticsBreastTask ForceProvidersComparison of epigenetic aging in normal breast tissue from women with and without breast cancer.
Hofstatter E, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Patwardhan G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. DOI: 10.1200/jco.2017.35.15_suppl.1522.Peer-Reviewed Original ResearchNormal breast tissueBreast cancerBreast tissueHealthy peersSusan G. Komen Tissue BankIU Simon Cancer CenterNormal breast tissue samplesBreast cancer preventionCohort of womenImportant risk factorKomen Tissue BankLifetime of womenBreast tissue samplesCurrent medicationsTumor characteristicsCancer CenterRisk factorsCancer preventionClinical dataFamily historyReduction mammoplastyHigh riskChronologic ageReproductive historyCancerSafety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.
Pusztai L, Silber A, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, Szekely B, Frederick C, Rispoli L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial. Journal Of Clinical Oncology 2017, 35: 572-572. DOI: 10.1200/jco.2017.35.15_suppl.572.Peer-Reviewed Original ResearchImmune related adverse eventsTriple-negative breast cancerWeekly nab-paclitaxelWeeks of therapyNeoadjuvant chemotherapyDose levelsNab-paclitaxelPhase I/II trialPathologic complete response rateChest X-ray abnormalitiesDoxorubicin/cyclophosphamidePhase I toxicityComplete response rateImmune checkpoint inhibitorsPhase I portionRelated adverse eventsPhase II portionPhase I partX-ray abnormalitiesNegative breast cancerSequential taxaneAnthracycline chemotherapyCheckpoint inhibitorsII trialAdverse eventsPathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.Peer-Reviewed Original ResearchPathologic complete response rateHER2-positive breast cancerDual HER2 blockadeComplete response ratePCR rateEstrogen receptorHER2 blockadeBreast cancerStage IResponse rateGrade 3/4 adverse eventsSymptomatic congestive heart failureClinical stage ICompletion of chemotherapyPhase II studyTaxane-based chemotherapyCongestive heart failureEfficacy of anthracyclinesPositive breast cancerNormal cardiac functionEntire treatment durationER cohortER- cancersNeoadjuvant pertuzumabWeekly paclitaxelManagement Strategies for Sexual Health After Breast Cancer Diagnosis
Overton E, Hofstatter E, Miller D, Ratner E. Management Strategies for Sexual Health After Breast Cancer Diagnosis. 2017, 303-322. DOI: 10.1007/978-3-319-42451-4_19.Peer-Reviewed Original ResearchEstrogen receptor-positive breast cancerReceptor-positive breast cancerModerate hot flashesPast medical historyLast menstrual periodBreast cancer diagnosisEndocrine therapyNight sweatsVaginal drynessVaginal symptomsHot flashesPainful intercourseMedical historyMenstrual periodBreast cancerSexual healthFemale presentsCancer diagnosisMonthsSignificant benefitsGabapentinTamoxifenTherapySymptomsCancer
2016
Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.
Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.Peer-Reviewed Original ResearchDefekte homologe Rekombination als einheitlicher Biomarker beim Mammakarzinom
Wahlde M, Timms K, Chagpar A, Wali V, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury J, Hatzis C, Hofstatter E, Pustzai L. Defekte homologe Rekombination als einheitlicher Biomarker beim Mammakarzinom. Senologie - Zeitschrift Für Mammadiagnostik Und -therapie 2016, 13 DOI: 10.1055/s-0036-1583463.Peer-Reviewed Original Research
2015
Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.
Timms K, Chagpar A, Wali V, Bossuyt V, Reid J, Gutin A, Neff C, Hofstatter E, Lanchbury J, Pusztai L. Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors. Journal Of Clinical Oncology 2015, 33: 1091-1091. DOI: 10.1200/jco.2015.33.15_suppl.1091.Peer-Reviewed Original ResearchDiscovery and disclosure of incidental genetic information obtained through high throughput sequencing.
Hofstatter E, Yushak M, Bouberhan S, Han G, Epstein L, Pusztai L. Discovery and disclosure of incidental genetic information obtained through high throughput sequencing. Journal Of Clinical Oncology 2015, 33: e17779-e17779. DOI: 10.1200/jco.2015.33.15_suppl.e17779.Peer-Reviewed Original Research